Brian Perry, MD
Otolaryngology · McAllen, TXNPI 1619915832
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.6%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Med-el Corporation at 58.6% of the total. 2025 is the largest year on record at $1,262, 4.6 times the $273 reported in 2019.
Across 30 payments — averaging $72.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Med-el Corporation$1K
- Cochlear Americas$737
- Supernus Pharmaceuticals, Inc.$66
- Amgen$43
- Teva Pharmaceuticals USA, Inc.$26
- ALON Medical Technology$17
- plus $16 from 1 others
Across 2 payments — averaging $722.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cochlear Americas$1K
What the payments were for
- Consulting fees$40018%
- Travel & lodging$74334%
- Food & beverage$1,04048%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Med-el Corporation | 8 | $1,278 |
| Cochlear Americas | 11 | $737 |
| Supernus Pharmaceuticals, Inc. | 5 | $66 |
| Amgen | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| ALON Medical Technology | 1 | $17 |
| Novartis | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,182 in reported general payments places this provider in the 55th percentile of 729 otolaryngology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 12 | $1,398 |
| Acetazolamide | 25 | $886 |
| Ciprofloxacin Hcl | 21 | $259 |
| Spironolactone | 23 | $154 |
| Promethazine Hcl | 15 | $141 |
| Amitriptyline Hcl | 23 | $99 |
| Clindamycin Hcl | 15 | $92 |
| Ondansetron OdtOndansetron | 15 | $89 |
| Hydrochlorothiazide | 12 | $67 |
| Tramadol Hcl | 17 | $44 |
| Diazepam | 12 | $34 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in McAllen
- James WrightMcAllen$15K
- Marc DeanFort Worth$486K
- Amber LuongHouston$426K
- Arjuna KuperanHouston$348K
- Ronald KuppersmithCollege Station$325K
- Ron KarniHouston$317K
- Philip ChenSan Antonio$305K
- Jordan RihaniSouthlake$280K
- Keith MathenyFrisco$269K
- Martin CitardiHouston$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.